Compare Fluor Corporation Common Stock (FLR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fluor Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? Fluor Corporation Common Stock trades at $47.02 (market cap $6.37B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Fluor Corporation Common Stock is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Fluor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fluor Corporation Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| FLR | TNGX | |
|---|---|---|
Market Cap | $6.37B | $3.74B |
Volume | 1,709,507 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $57.50 | $32.90 |
52-Week Low | $39.63 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.40B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fluor Corporation (FLR) trades at $49.75, showing minimal daily movement with a 0.08% gain. The stock faces bearish technical signals but maintains analyst support with a $62.33 consensus price target. Recent Q2 2026 earnings beat expectations, though profitability remains challenged with negative margins. The company secured a significant $7.5 billion LNG Canada Phase 2 project, providing substantial future revenue visibility amid ongoing operational restructuring.
FLR presents a turnaround opportunity with strong backlog coverage but carries execution risks. The stock trades at attractive valuation multiples (P/S 0.49) with 53.6% analyst buy ratings, yet negative cash flow and margin pressures require careful monitoring. Near-term performance hinges on successful project execution and margin improvement from the shift to reimbursable contracts.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fluor Corporation Common Stock
Fluor provides engineering, procurement, construction, and maintenance services. It works across energy, infrastructure, mining, advanced technology, manufacturing, life sciences, and government projects.
Read more on FLR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
